In conclusion, IL-13Rα2 can be a potential diagnosis and prognostic biomarker and a marker for therapeutic response to conventional as well as cutting-edge cellular and gene therapy approaches for pancreatic cancer. The gene discussed is IL13RA2; the disease is familial pancreatic carcinoma.